Neurotoxin Comparison: Botox vs Dysport vs Jeuveau vs Daxxify vs Xeomin

Botox, Dysport, and Xeomin reach visible effect in 3–7 days, with full effect by 10–14 days. Jeuveau matches this timeline. Daxxify stands apart: onset begins at 2–3 days and reaches plateau by day 7, making it the fastest-acting option—a meaningful clinical advantage for patients seeking rapid results or those scheduling before events.

Duration is where the real divergence emerges. Botox, Dysport, and Xeomin last 12–16 weeks on average; Jeuveau similarly lasts 12–16 weeks. Daxxify extends to 6 months (24 weeks) in many patients, a 50% duration advantage that reshapes the economics of repeat visits and annual patient lifetime value. Faster onset plus longer duration makes Daxxify a premium positioning play, though at higher per-unit cost.

Clinical consistency matters: Botox and Xeomin have the longest track record and highest physician familiarity. Dysport has a reputation for faster diffusion (wider spread), useful for larger treatment areas but requiring careful dosing near the eyes. Jeuveau and Daxxify are newer entrants with growing but smaller clinical datasets in practice.

Neuromodulator units are not interchangeable across products. Each brand is potency-calibrated to its own standard, and conversion ratios are clinical approximations, not exact equivalencies.

Standard conversion benchmarks (used by most practitioners):

• Botox to Dysport: roughly 1:3 (1 unit Botox ≈ 3 units Dysport)
• Botox to Jeuveau: roughly 1:1 (equipotent)
• Botox to Xeomin: roughly 1:1 (equipotent)
• Botox to Daxxify: roughly 1:1 (equipotent)

These ratios are clinical consensus, not FDA-mandated, and individual patient response varies. A patient accustomed to 20 units of Botox may need 60 units of Dysport for equivalent effect, or 20 units of Jeuveau. Dysport's wider diffusion profile means some practitioners dose it lower in periocular zones to avoid unintended spread. Document conversion clearly in patient records to avoid overdosing on switch and to manage patient expectations about unit counts.

Wholesale cost per unit varies by volume tier, rebate program, and manufacturer relationship. Botox (AbbVie) and Dysport (Galderma) have the most mature rebate infrastructure through Alle (Allergan/AbbVie) and Aspire (Galderma), respectively. Jeuveau (Evolus) operates Evolus Rewards. Daxxify (Revance) and Xeomin (Merz) have smaller loyalty programs.

Retail pricing typically ranges $10–$15 per unit across brands at the practice level, though premium positioning (especially Daxxify's longer duration) can command $12–$18 per unit. A 20-unit glabellar treatment thus costs the patient $200–$360 depending on brand and geography.

From a practice cost standpoint, Botox and Dysport offer the deepest volume discounts and rebate dollars, making them economically attractive for high-volume practices. Jeuveau targets price-sensitive practices with competitive per-unit wholesale costs. Daxxify, despite higher per-unit cost, can justify premium pricing due to 6-month duration; a patient paying $300 for 6 months of effect ($50/month) may perceive better value than $240 every 3 months ($80/month). Xeomin occupies a middle ground with modest loyalty incentives.

Track your actual cost per unit (including rebates) and your average patient spend per treatment to model cash flow. A practice doing 100 treatments per month at 20 units per treatment (2,000 units) will see meaningful margin differences between brands.

Dysport is known for broader diffusion—toxin molecules spread further from the injection site. This can be advantageous for large forehead lines or when a softer, more natural look is desired, but it increases the risk of unintended spread into the orbicularis oculi (causing ptosis) if injected too close to the brow. Experienced injectors often dose Dysport lower in sensitive zones.

Botox, Jeuveau, Xeomin, and Daxxify have tighter diffusion profiles, allowing more precise, localized effect. This is especially valuable in the periocular region and for patients who want targeted correction without "frozen" appearance.

Xeomin is protein-free (no complexing proteins), which theoretically reduces antibody formation and resistance over time—relevant for long-term patients, though clinical resistance to any neurotoxin is rare in aesthetic practice. Botox and Dysport carry complexing proteins that some practitioners believe increase resistance risk with repeated use, though evidence is mixed.

Choose your primary brand based on your patient population's aesthetic goals and your injector's comfort. Offering two brands (e.g., Botox for precision, Dysport for diffusion) gives flexibility; stocking all five dilutes inventory and complicates ordering.

Botox remains the category leader by volume and brand recognition; patients often ask for it by name. AbbVie's scale, rebate programs, and clinical support give it distribution and pricing power. However, Botox faces generic/biosimilar pressure in the long term (though no approved biosimilar exists in the U.S. aesthetic market as of 2026).

Dysport (Galderma) competes on diffusion profile and loyalty incentives; Galderma has been aggressive in capturing market share through Aspire rebates and bundling with filler products (Restylane family).

Jeuveau (Evolus) positioned itself as a lower-cost alternative and has gained traction in price-sensitive markets and with practices seeking to diversify away from AbbVie. Evolus Rewards offers competitive rebates.

Daxxify (Revance) is the newest entrant with the longest duration; it commands premium pricing and appeals to practices and patients willing to pay more for convenience and fewer appointments. Revance's smaller scale means fewer rebate dollars but also less channel conflict.

Xeomin (Merz) occupies a niche as the protein-free option and appeals to practices emphasizing scientific differentiation, though it has not captured significant market share in the U.S. aesthetic market.

No single brand dominates all dimensions. Your choice should align with your patient demographic, pricing strategy, and rebate leverage. High-volume practices benefit from Botox or Dysport rebates. Practices emphasizing premium, convenience-driven care may favor Daxxify. Budget-conscious practices may lean Jeuveau.

All five products are FDA-approved for glabellar lines (frown lines). Botox and Dysport carry the broadest approved indications, including crow's feet and forehead lines. Jeuveau is approved for glabellar lines only (though off-label use for other areas is common). Daxxify is approved for glabellar lines. Xeomin is approved for glabellar lines and crow's feet.

Supply chain stability matters: AbbVie (Botox) and Galderma (Dysport) have mature, redundant manufacturing. Evolus (Jeuveau) and Revance (Daxxify) are smaller manufacturers; supply disruptions, though rare, are more plausible. Merz (Xeomin) is stable but has smaller U.S. market presence.

Verify your state's scope-of-practice and supervision rules. Most states allow nurse injectors and physician assistants to administer neurotoxins under physician supervision; a few restrict to physicians only. Confirm your state board's requirements and your malpractice carrier's coverage for each brand.

Keep detailed records of lot numbers, expiration dates, and patient outcomes. Neurotoxins are temperature-sensitive; improper storage (above 25°C or freezing) degrades potency. Rotate stock by expiration date and discard expired product.